PHVS — Pharvaris NV Share Price
0.000.00%
Last trade - 00:00- $917.66m
- $599.62m
- 48
- 19
- 72
- 44
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.02 | ||
| Price to Tang. Book | 3.02 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -54.28% | ||
| Return on Equity | -41.18% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | n/a | n/a | n/a | n/a | n/a | n/a | 1.68 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 30th, 2015
- Public Since
- February 5th, 2021
- No. of Employees
- 108
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 54,493,142
- Address
- Emmy Noetherweg 2, LEIDEN, 2333 BK
- Web
- https://pharvaris.com/
- Phone
- +31 712036410
- Auditors
- PricewaterhouseCoopers Accountants N.V.
Upcoming Events for PHVS
Q1 2025 Pharvaris NV Earnings Release
Pharvaris NV at Bank of America Global Healthcare Conference
Pharvaris NV Annual Shareholders Meeting
Q2 2025 Pharvaris NV Earnings Release
Similar to PHVS
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Pharvaris NV share price?
As of Today at 22:38 UTC, shares in Pharvaris NV are trading at $16.84. This share price information is delayed by 15 minutes.
How has the Pharvaris NV share price performed this year?
Shares in Pharvaris NV last closed at $16.84 and the price had moved by -26.04% over the past 365 days. In terms of relative price strength the Pharvaris NV share price has underperformed the S&P500 Index by -31.74% over the past year.
What are the analyst and broker recommendations for Pharvaris NV?
The overall consensus recommendation for Pharvaris NV is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Pharvaris NV dividend yield?
Pharvaris NV does not currently pay a dividend.
Does Pharvaris NV pay a dividend?
Pharvaris NV does not currently pay a dividend.
When does Pharvaris NV next pay dividends?
Pharvaris NV does not currently pay a dividend.
How do I buy Pharvaris NV shares?
To buy shares in Pharvaris NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Pharvaris NV?
As of the previous close price of $16.84, shares in Pharvaris NV had a market capitalisation of $917.66m.
Where are Pharvaris NV shares listed?
Here are the trading details for Pharvaris NV:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: PHVS
What kind of share is Pharvaris NV?
Based on an overall assessment of its quality, value and momentum Pharvaris NV is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Pharvaris NV share price forecast for 2025?
The analyst consensus target price for shares in Pharvaris NV is $34.10. That is 102.47% above the last closing price of $16.84.
Analysts covering Pharvaris NV currently have a consensus Earnings Per Share (EPS) forecast of -€3.32 for the next financial year.
Find out moreWhat is the trend in the Pharvaris NV share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pharvaris NV. Over the past six months, its share price has underperformed the S&P500 Index by -18.24%.
As of the last closing price of $16.84, shares in Pharvaris NV were trading -7.63% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Pharvaris NV PE Ratio?
The Pharvaris NV PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $16.84.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Pharvaris NV?
Pharvaris NV's management team is headed by:
- Berndt Modig - CEO
- Jochen Knolle - CFD
- Anne Lesage - CFD
- Morgan Conn - OTH
- Peng Lu - OTH